ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts ...

Eyestem Research Pvt Ltd announced positive results from its phase 1/2 trial ( NCT06394232) evaluating its investigational ...

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Biocon Biologics and Regeneron settled to commercialize aflibercept-jbvf in the US, resolving patent litigation. The agreement allows Biocon to launch Yesafili in the US by the second half of 2026, or ...

A study analyzed the geographic and institutional disparities in clinical trial distribution for candidates targeting the ...

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal ...

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular ...